Fight the SARS-CoV-2 pandemic

The contribution of National Promotional Banks and Institutions in Europe
Preface by ELTI President Laurent Zylberberg

The Covid-19 pandemic has already been dominating our lives for over a year. As a result, the European economy and the life of nearly 450 million European citizens have been heavily affected. Mid-May 2021, more than 31 million people have suffered from an infection as a result of the covid-19 virus and more than 700,000 people have died in Europe as a consequence of the pandemic.

National Promotional Banks and Institutions (NPBIs) launched an impressive and unbureaucratic effort in April 2020 to assist companies within their countries after the lock-down. When compared to the figures in 2019, many ELTI members have doubled their commitments this past year both in numbers of loans and investments as well as in the total amount of funds committed. In many cases, a few thousand Euros helped the companies to survive and whilst larger investments of billions of Euros brought about a continuation of essential business. Millions of jobs were saved. Bridging the liquidity gap, providing additional equity and helping the economy to prepare for the recovery are important elements of NPBIs support.

In addition, ELTI members have provided funds and taken multiple large-scale risks to fight against the pandemic. These include the financing of companies, projects or initiatives which address the global health situation directly like through biotech firms to develop effective vaccines, production of more efficient sanitising devices, investments in intensive-care facilities or agile high-tech companies which provide an AI-platform for a more efficient exchange between research institutions. All of these were and still are important elements to overcoming the pandemic. These ventures serve as an important dimension of NPBIs role within their countries and societies. European citizens are directly benefitting from these investments.

In this booklet you find a few impressive examples from different European countries which should provide an overall idea on the broad variety of NPBIs activities throughout all over Europe, all of whom are working under a common goal: to help rebuild the livelihoods of European citizens and to revitalise the European economy.

Take care

Laurent Zylberberg
ELTI President
## Contents

### Belgium

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biogazelle, Zwijnaarde, Ghent</td>
<td>06</td>
<td>Combining cutting-edge science with high quality to accelerate drug development</td>
</tr>
<tr>
<td>Argenx, Zwijnaarde, Ghent</td>
<td>08</td>
<td>Reaching Patients Through Immunology Innovation</td>
</tr>
<tr>
<td>MyNEO, Ghent</td>
<td>09</td>
<td>myNEO’s universal SARS-CoV-2</td>
</tr>
</tbody>
</table>

### Bulgaria

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doordesfecto (Univalent), Sofia</td>
<td>12</td>
<td>New normal in infection prevention: disinfection</td>
</tr>
</tbody>
</table>

### France

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sèmeia</td>
<td>15</td>
<td>Easy access to medical data</td>
</tr>
</tbody>
</table>

### Germany

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>KFW</td>
<td>19</td>
<td>“We have a reason to be optimistic”</td>
</tr>
<tr>
<td>Uvis, Cologne</td>
<td>20</td>
<td>Germ-free up the escalator</td>
</tr>
</tbody>
</table>

### Hungary

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virus Buster, Budapest</td>
<td>22</td>
<td>Hand Sanitizer Compliance System</td>
</tr>
</tbody>
</table>

### Italy

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kither Biotech, Torino</td>
<td>24</td>
<td>The future in a small molecule</td>
</tr>
<tr>
<td>University Hospital, Parma</td>
<td>25</td>
<td>New sanitary structures and technologies in Parma</td>
</tr>
<tr>
<td>Gpi, Trento</td>
<td>27</td>
<td>Cutting-edge solutions for sustainable health</td>
</tr>
</tbody>
</table>

### Poland

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BGK Novar</td>
<td>29</td>
<td>From Hand Sanitizers to Soap Dispensers</td>
</tr>
<tr>
<td>Temporary Hospital, Siedlce</td>
<td>30</td>
<td>Temporary hospital in Siedlce</td>
</tr>
<tr>
<td>National COVID-19 hotline, Warsaw</td>
<td>31</td>
<td>National COVID-19 Vaccination Program hotline</td>
</tr>
</tbody>
</table>
BELGIUM
Combining cutting-edge science with high quality to accelerate drug development

Biogazelle is a CRO specializing in high-value applications to support pharmaceutical research, clinical trials and diagnostic test development. Read more about it here.

Biogazelle is ISO17025 accredited for qPCR test development and its use in clinical trials. We have wet-lab validated more than 100,000 qPCR assays, beyond industry standards, of which the SARS-CoV-2 assay is just one. Additionally, Biogazelle has co-authored the MIQE guidelines for design, execution, analysis, and reporting of qPCR studies, with more than 10,000 citations.

We have validated both E (envelope) and N (nucleoprotein) gene assays for RT-qPCR. Applying both assays result in 99.99% coverage of known SARS-CoV-2 viral genomes, and also provides increased sensitivity. We have implemented multiple controls in our platform, namely an internal spike-in RNA to test the efficiency of RNA extraction and RT-qPCR of each sample, and 1 positive and negative workflow control per batch of 93 samples. Finally, we have introduced digital PCR as an orthogonal validation method and to calibrate our platform.

Biogazelle gebruikt RNA-analyse als diagnose- en therapiemodel. Ribonucleïnezuur, vaak afgekort tot RNA, is samen met DNA en eiwitten een van de drie macromoleculen die essentieel zijn voor alle bekende levensvormen. Door RNA uit te lezen, krijgt men een beeld van wat er misloopt binnen een bepaalde cel, en hoe dat tot kanker leidt. Weten waar en op welke manier het misloopt: dat is belangrijk om te bepalen of een bepaalde therapie al dan niet kan werken, en om die te verfijnen. Biogazelle-oprichter Jan Hellemans verklaart: “Vroeger was een longkanker gewoon longkanker. Nu is de longkanker die persoon A heeft een andere longkanker dan die van persoon B. Dankzij een verfijndere analyse kunnen we de therapie beter afstemmen op wat er misloopt, en kunnen we ook denevenwerkingen veel meer beperken”.

Discover more here or visit biogazelle.com/solutions
Reaching Patients Through Immunology Innovation

The immune system is the body's defence system against infection and other diseases. In the case of autoimmune diseases, the immune system mistakenly identifies part of its own body as an invader and produces antibodies to attack its tissues and cells. In many cases, it is not known what causes the immune system to initiate this autoimmune response. Examples of autoimmune diseases argenx is researching are myasthenia gravis, immune thrombocytopenia, chronic inflammatory demyelinating neuropathy and pemphigus vulgaris.

In each of these diseases, a particular type of antibody called IgG (immunoglobulin G) are often the cause of the disease.

Partners met een verre blik

Maar, het aanmaken van biologische geneesmiddelen is een zeer duur proces. Het materiaal en de opstart van de productie nemen tijd en geld in beslag. “Onze technologie is bijzonder productief: toen we de laatste financieringsronde hielden, hadden we nog niet het voornemen om met ARGX-113 klinische proeven te gaan doen. Maar de molecule bleek zo veelbelovend dat we besloten het proces hiervoor te versnellen. Daarvoor was natuurlijk nieuw kapitaal nodig.” Het was PMV die over de brug kwam. De investeringsmaatschappij investeerde 5 miljoen euro in argenx, specifiek voor het verder ontwikkelen en naar de markt brengen van hun meest recente antistof, ARGX-113. Tim Van Hauwermeiren getuigt enthousiast: We waren erg blij met PMV in zee te kunnen gaan: zij is een strategische aandeelhouder waar meer op de agenda staat dan alleen financiële return. PMV ondersteunt ons om te doen wat juist is, ook al duurt het wat langer. Dat is niet onbelangrijk, want het duurt vandaag twaalf tot veertien jaar om een medicijn op de markt te krijgen.

Discover more here or visit argenx.com
myNEO’s universal SARS-CoV-2 vaccine approach

The myNEO technology platform focuses on identifying, exploring and validating unusual alterations and their immunogenic impact. In a personalised manner, the sequencing data of tumour cells (biopsy) and healthy cells (blood) are compared, and tumour-specific alterations leading to peptides present on the tumour surface are annotated.

Since these antigens are absent from healthy cells, they can have important immunogenic implications, and are fit for use in therapeutic or prognostic applications. The bioinformatic platform is incorporated in a comprehensive end-to-end flow ranging from sample processing to vaccine construct design.
myNEO announced in May 2020 the identification of promising immunogenic covid-19 peptides by making smart use of its computational algorithms which resulted in pre-clinical testing of five covid-19 vaccine designs.

The vaccine works differently than most. It consists of a carefully chosen cocktail of peptides (pieces of protein), identified by myNEO, that are essential for the virus, to initiate a highly targeted immune response. This approach has several advantages over using a complete protein. By specifically choosing conserved fragments that are necessary for the virus to work, the vaccine has a better effect against both SARS-CoV-2 (the virus responsible for Covid-19) and all other (future) forms of the same virus family with those same parts.

Klinische testen op mensen vanaf 2021

Nu myNEO deze veelbelovende Covid-19 peptiden gevonden heeft, start het bedrijf preklinische proeven in samenwerking met een Europees biotech bedrijf met een kankervaccintechnologie. Het doel is om het vaccin begin 2021 te testen op mensen.

“Het is heel belangrijk om goed te evalueren tegen welke specifieke onderdelen van het Covid-19 virus we willen vaccineren. Er is namelijk een verschil tussen een vaccin dat langdurige immuniteit biedt tegen alle gekende vormen en verwanten van Covid-19, en een vaccin dat alleen binnen bepaalde selecte bevolkingsgroepen resultaten oplevert.” zegt Cedric Bogaert, CEO van myNEO. “Gelukkig kunnen we veel opsteken van de andere coronavirussen die in de afgelopen decennia zijn opgeflakkerd.”

Discover more here

or visit myneo.me/en
The Bulgarian company UniValent Ltd. is focused on creating innovative and reliable solutions that deliver improved disinfection systems. We have developed new products that help businesses protect their employees and visitors as they reopen and resume operations, while applying the highest health and safety standards.

Our fast and effective modular disinfection systems can easily be installed in offices, public venues and commercial buildings. Our products help businesses maintain safer environments for work and leisure while responding to changes in consumer expectations and behaviour.

We have designed several automated walk-through disinfection doorframes suitable for a wide-range of locations and applications. For more information, please visit www.doordesfecto.eu.

Morningside Hill Venture Capital

Morningside Hill Venture Capital is focused on providing growth capital (EUR38.5M) to Bulgarian start-up companies as equity (or equivalent). The public funds (EUR33.3M) are provided by Fund Manager of Financial Instruments in Bulgaria (FMFIB) EAD under the Operational Programme “Innovation and Competitiveness” co-financed by the European Regional Development Fund (ERDF).

or visit https://doordesfecto.eu/en/
FRANCE
Easy access to medical data

As part of its ambitious investment recovery plan, CDC (Banque des Territoires) is investing in Sêmeia, a health-care start-up which has developed an innovative tool to improve the medical monitoring of patients. This digital device offers medical institutions and professionals an efficient and easy access to relevant medical data related to their patients, as well as smart alerts generated thanks to big data and artificial intelligence.

Sêmeia en bref

Fondé en 2017 par Mathieu Godart, Pierre Hornus et Daniel Szeftel

Service de télésuivi sur la néphrologie, les maladies mentales, l’oncologie et les maladies auto-immunes

23 collaborateurs à Toulouse et Paris + un comité scientifique indépendant

20 établissements utilisateurs

Sêmeia, propose aux établissements et aux professionnels de santé un service innovant de télésuivi appuyé par l'intelligence artificielle pour améliorer la prise en charge des patients et simplifier la vie des soignants.

Fondé en 2017 par 3 associés, Sêmeia est né d’un constat simple : si les bénéfices cliniques et médico-économiques d’un suivi renforcé des patients sont reconnus par tous, le temps médical et infirmier disponible ne permet pas de mettre un soignant derrière chaque patient.

Discover more here

or visit  https://semeia.io
Covid-19 – Open AI Consortium

Bpifrance, through its “Large Venture” fund, has invested in the Owkin startup in May 2020. Created in 2016, Owkin offers solutions based on artificial intelligence (AI) and aims to improve the performance of research activities of pharmaceutical and academic laboratories.

During the global health crisis, Owkin introduced the “Covid-19 Open AI Consortium (COAI)” to increase collaborative research, accelerate clinical development of effective treatments for Covid-19, and share all its findings with the global medical and scientific community.

Indeed, healthcare systems and clinicians are overwhelmed by the number of patients and lack of reliable methodologies to assess disease evolution to improve patient treatment and anticipate bottlenecks in the healthcare systems. AI models, built on clinical records, radiology, laboratory, and demographic data can help predict prognosis, response to treatment, adverse events, public health risks, and other challenging scientific questions.

Discover more here
or visit www.owkin.com

Lors de la crise sanitaire, Owkin a lancé le « Covid-19 Open AI Consortium (COAI) » pour accroître la recherche médicale collaborative, accélérer le développement de traitements efficaces contre la Covid-19 et à partager ces résultats avec la communauté médicale et scientifique mondiale.

En effet, les systèmes de santé et les médecins sont submergés par le nombre de patients, le manque de méthodologies fiables pour évaluer l’évolution de la maladie et ainsi améliorer la qualité de la prise en charge des patients. Les modèles d’IA de Owkin, construits à partir de dossiers médicaux (données radiologiques, données démographiques, etc.) contribuent à définir le bon diagnostic, la réponse au traitement, les effets indésirables ainsi que d’autres questions scientifiques complexes.

Discover more here

or visit www.owkin.com
GERMANY
“Diagnostics: We have reason to be optimistic”

Investments in health

KfW Capital, the subsidiary of KfW Group, has invested in the Venture Capital fund TVM Capital, which finances Centogene. “Particularly in the current situation, it is clear how important investments in the development of active substances in the health sector are,” says Jörg Goschin, Managing Director of KfW Capital.

400 Centogene employees now generate sales of 50 million euros, mainly in America and Asia. In its Rostock laboratories, Centogene searches patient DNA for rare genetic diseases and has the world’s largest database in this field. It stores genetic information from half a million patients from around 120 countries.

In combination with the expertise of the treating physician, the Rostock researchers can use a patient’s genes to diagnose whether the patient suffers from a rare disease or is likely to develop it. The result in turn is the basis for therapy.

Responsibility in times of crisis: a Rostock-based company that otherwise tracks rare diseases is opening its laboratories for life-saving coronavirus tests. Up to 10,000 swabs can be analysed per day.

Centogene started conducting tests in its own company in mid-March. Each and every person was tested for the novel coronavirus Covid-19. Only one employee tested positive. She went into quarantine, but the others were able to continue working after the series of tests were completed. Some of them, however, are currently working on completely different things than before: they are analysing coronavirus tests. Centogene took the initiative and is providing laboratory capacity for virus testing.

Centogene was founded in 2006 as a spin-off of the University Medicine Rostock and listed the company on the New York technology exchange Nasdaq last year. The company’s activities in the fight against the coronavirus are far removed from its actual purpose: Centogene is the global market leader in diagnostics for rare congenital diseases and is now helping to contain an epidemic that affects everyone.

In its Rostock laboratories, Centogene searches patient DNA for rare genetic diseases and has the world’s largest database in this field.

Discover more here

https://www.centogene.com
Germ-free up the escalator

UVIS UV-Innovative Solutions GmbH offers hygiene technology with a focus on UVC products for the disinfection of surfaces, especially escalators, as well as antimicrobial coatings. These technologies render 99.99 percent of germs, viruses and bacteria harmless. In the COVID-19 pandemic, where hygiene plays an important role in containing the virus, the products of the Cologne-based company are in higher demand than ever before, both nationally and internationally.

Discover more here

or visit https://www.kfw.de/stories/gesellschaft/gesundheit/curevac/

UVIS Managing Directors Tanja Zirnstein (l.) and Katharina Obladen.


Dass Tanja Zirnstein und Katharina Obladen ihre Geschäftsidee, die ursprünglich im Rahmen eines Schülerwettbewerbs entstanden ist, zum Fliegen bringen konnten, verdanken sie dem Programm „NRW.Seed-Cap“. Mit diesem Produkt stellt die NRW.BANK gemeinsam mit privaten Investoren jungen, innovativen Unternehmen häufig die erste Finanzierung zur Verfügung.
VB Hand Sanitizer Compliance System

The coronavirus disease 2019 (COVID-19) pandemic has increased dramatically the demand for hand sanitizers. Hand hygiene is essential for preventing hospital-acquired infections but is difficult to accurately track. If hands are not visibly soiled, the WHO recommends the use of an alcohol-based hand rub for routine decontamination of hands in all clinical situations. We also know that alcohol-based hand hygiene requires less time than washing with soap (plain or medicated) and water, but is as effective for most pathogens.

Covid-19 és a kézfertőtlenítés

A COVID-19 világjárvány kirobbanását követő rendkívüli helyzetben a kézfertőtlenítő termékek piacán a katasztrófához mérhető árrobbanást az alacsony, nem megfelelő minőségű termékek megjelenése követte.

A Virus Buster Kft és a hálózat fejlesztést és értékesítést végző partnere a Hinergenius Kft tulajdonosai felismerték az igényt egy jó minőségű, megbízható megoldásra, amely megfelel a magyar fogyasztói igényeknek és a stabil, hazai beszállítói kapcsolatok révén széles körben elérhető megoldást nyújt. Ügyfeleink a kiskereskedelmi szektor és egyéb nagy ügyfélforgalmat lebonyolító szolgáltatok, valamint a közszféra. Közös célunk, az egészség megőrzésének elérésének érdekében nemcsak hosszú távú megállapodást kötünk a legmegbízhatóbb vegyianyag gyártókkal. Elkezdttük fejleszteni saját hardvereinket (legmodernebb érintésmentes adagolók).

Discover more here or visit https://virus-buster.hu/rolunk/
ITALY
The future in a small molecule

Kither Biotech is a biotech company developing novel therapies for rare pulmonary diseases with high unmet medical needs. Founded in Turin (Italy) by Prof. Emilio Hirsh and Prof. Alberto Bardelli (founder of Horizon Discovery), further supported by Dr. Laura Iris Ferro (former CEO of Gentium) and Dr. Vincent Metzler (senior biopharma industry executive). The key product is a patented compound to treat Cystic Fibrosis (CF) with preclinical data showing strong superiority vs. the current market leader, with the potential to radically change the treatment paradigm of CF, a genetic disorder with life expectancy inferior to 40 years and with a strong need for an effective treatment that is still unaddressed.

The pipeline also includes a proprietary small molecule that has shown strong results in pre-clinical models for Idiopathic Pulmonary Fibrosis (IPF), with a potential long-term use for severe form of COVID-19 patients that develop pulmonary fibrosis. Kither Biotech has already raised €5.6m from CDP Venture Capital Sgr and other investors. Now is raising a second round aimed to complete the CF development program for clinic trial, and to launch the pre-clinical development of the molecule for the treatment of IPF.

Discover more here

or visit http://kitherbiotech.com/it

Kither Biotech è una società di biotecnologie che sviluppa nuove terapie per malattie polmonari rare con elevati bisogni clinici insoddisfatti. Fondata a Torino dal Prof. Emilio Hirsh e dal Prof. Alberto Bardelli (fondatore di Horizon Discovery), è supportata anche dalla Dott.ssa Laura Iris Ferro (ex CEO di Gentium) e dal Dott. Vincent Metzler (dirigente senior dell’industria biofarmaceutica). Il prodotto chiave è un composto brevettato per il trattamento della Fibrosi Cistica (CF) con dati preclinici che mostrano una forte superiorità rispetto all’attuale leader di mercato, con il potenziale per cambiare radicalmente il paradigma di trattamento della FC, una malattia genetica con aspettativa di vita inferiore a 40 anni e con un forte bisogno di trattamento efficace che è ancora irrisolto. La pipeline include anche una piccola molecola proprietaria che ha mostrato ottimi risultati in modelli preclinici per la Fibrosi Polmonare Idiopatica (IPF), con un potenziale utilizzo a lungo termine su pazienti gravemente affetti da COVID-19, che sviluppano fibrosi polmonare.

Kither Biotech ha già raccolto 5,6 milioni di euro da CDP Venture Capital Sgr e altri investitori. Ora sta raccogliendo un ulteriore round volto a completare il programma di sviluppo della FC per la sperimentazione clinica e per avviare lo sviluppo preclinico della molecola per il trattamento dell’IPF.
New sanitary structures and technologies in Parma

The University Hospital of Parma is a multi-specialized structure that provides citizens with a complete offer of diagnostic, therapeutic and rehabilitative services. It counts 1,044 beds and it is divided into 7 departments with integrated activities and an intercompany department.

There are 800 scientific researchers working in 70 multidisciplinary teams synergically using cutting-edge technologies and highly qualified personnel.

Over the last three years the University Hospital produced more than 1,400 publications with 11,740 citations in international scientific papers and 300 studies started, of which 35% promoted by the University Hospital itself.

In this context, Cassa Depositi e Prestiti subscribed a financing contract that will allow the University Hospital of Parma to support investments to realise new facilities – as the new integrated cancer center and the new digestive endoscopy department – and support new technologies and excellent health services, fueling research and clinical care.

Parma, is the second most populous city in the northern Italian region of Emilia-Romagna with a population of almost 200 thousand. The city is home to the University of Parma, one of the oldest universities in the world.
L’Azienda Ospedaliero-Universitaria di Parma è una struttura polispecialistica che offre ai cittadini un quadro completo di servizi diagnostici, terapeutici e riabilitativi, dotato di 1.044 posti letto e si articola in 7 dipartimenti ad attività integrata e un dipartimento interaziendale.

Sono 800 i professionisti impegnati nella ricerca scientifica che compongono gli oltre 70 team multidisciplinari che lavorano in sinergia utilizzando tecnologie all’avanguardia e avvalendosi di personale altamente qualificato. Nell’ultimo triennio sono state prodotte 1.400 pubblicazioni, con 11.740 citazioni in lavori scientifici internazionali e 300 studi avviati, dei quali per il 35% l’Azienda Ospedaliero-Universitaria di Parma è promotore.

Il risultato di questo costante impegno nella ricerca si può riassumere in poche parole: più speranza, risposte rapide, assistenza ottimale per i pazienti, più salute.

In questo contesto Cassa Depositi e Prestiti, ha sottoscritto un contratto di finanziamento per proseguire gli investimenti al fine di realizzare nuove strutture – come il nuovo centro oncologico integrato e il nuovo reparto di endoscopia digestiva – e supportare lo sviluppo di nuove tecnologie, strumentazioni mediche e servizi sanitari d’eccellenza continuando ad affiancare
**Cutting-edge solutions for sustainable health**

Gpi is a strategic partner for software, technologies and services dedicated to Health, Social and Public Administration. Founded over 30 years ago in Trento, the company is leader in information systems and services for health and social care with more than 50 operating locations throughout Italy, as well as being present, with an international branched network, in Germany, Austria, France, Spain, the United States, Poland and Russia.

Gpi has grown over the years thanks to significant investments in research and development and accompanying in the path of innovation social and health organizations, proposing cutting-edge technologies and new models of care, treatment and prevention. A work carried out also thanks to the numerous partnerships with the main Italian universities and research hubs to transfer the scientific, technological and process knowledge applied to the e-health, e-welfare, well-being sectors.

Cassa Depositi e Prestiti confirmed its support for Gpi’s development plan, through a financing contract that will support its investments in research and development, provided for in the Industrial Plan.

Gpi’s mission: to create cutting-edge solutions to make health systems sustainable and improve people’s quality of life

Discover more here
or visit www.gpi.it
POLAND
From display stands to sanitizer dispensers

Novar is a family-owned company producing advertising and display stands and store equipment for over 25 years. Thanks to the BGK’s Biznesmax guarantee, Novar launched an innovative project to help fight the spread of COVID-19. Not only did the company designed a new model of the hand sanitizer dispenser and manufactured its elements, but it also developed and assembled the dispenser’s electronics in-house. Devices are equipped with an additional power supply, which means they can be placed anywhere, and their use is contactless. The company also provides the disinfectant liquid as a part of the package making the devices ready to use upon delivery.

Toruniem od 25 lat produkuje stojaki reklamowe i ekspozycyjne. Dzięki gwarancjom Biznesmax z pakietu pomocowego BGK nie tylko przetrwała pandemię, ale i uruchomiła innowacyjny projekt, pomagający w walce z rozprzestrzenianiem się wirusa. Novar zatrudnił elektroników do zbudowania układu sterującego urządzeniami do dezynfekcji. Za sprawą dodatkowego zasilania automaty można umieścić w dowolnym miejscu, a ich używanie jest bezdotykowe. W pakiecie dostarczany jest też płyn do dezynfekcji, dzięki czemu zakupione urządzenie jest od razu gotowe do użycia.

Gwarancja Biznesmax jest bezpłatną gwarancją spłaty kredytu dla MSP udzielaną z Funduszu Gwarancyjnego wsparcia innowacyjnych przedsiębiorstw Programu Operacyjnego Inteligentny Rozwój. Gwarancja zabezpiecza spłatę kredytów finansujących rozwój działalności gospodarczej, w tym projekty inwestycyjne o charakterze innowacji proekologicznej z efektem ekologicznym.
BGK supports the health care sector in Poland using its own financial resources. In 2020, the BGK Foundation donated PLN 1.5 million to support ten hospitals fighting against COVID-19. In its fight against the pandemic, BGK does not hesitate to get involved in projects outside its normal operations. For example, it provided technical and financial support in the creation of a temporary hospital in Siedlce, which can accommodate up to 100 patients, including ten who need intensive respiratory care. BGK’s HR department also assisted the hospital management in medical and technical staff recruitment.
National COVID-19 Vaccination Program hotline

BGK’s call centre employees were delegated, on a voluntary basis, to the National COVID-19 Vaccination Program hotline, helping Polish residents sign up for vaccinations.

Zadzwoń na całodobową i bezpłatną infolinię - 989.

Możesz to zrobić sam lub może Cię zapisać ktoś bliski z rodziny. Do zapisu wystarczy numer PESEL. Numer telefonu komórkowego nie jest wymagany, ale jeśli go podasz, otrzymasz SMS z potwierdzeniem umówienia wizyty na szczepienie. W ten sposób możesz zarejestrować swoich dziadków lub rodziców. Wystarczy, że rozpocznie się etap szczepień i będziesz miał numer PESEL bliskiej osoby.

Podczas rejestracji wybierzesz dokładny termin oraz miejsce szczepienia. Następnie - jeśli podałeś numer telefonu - otrzymasz SMS z potwierdzeniem umówienia wizyty na szczepienie.